BioCentury

8:00 AM GMT, Jan 23, 2006
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Strategy

Protein space race continues

Two recent deals by Ablynx N.V. illustrate the ongoing rush by big pharma companies to make sure they are players in the next-generation antibody/protein space.

In the past two weeks, Ablynx has signed deals covering therapeutic applications of its Nanobody platform with Novartis AG (NVS; SWX:NOVN, Basel, Switzerland) and Centocor Research & Development Inc. (Malvern, Penn.), a subsidiary of

Read the full 586 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.